Journal Scans
Treatment by Lenalidomide in Lower Risk Myelodysplastic Syndrome With 5q Deletion—The GFM Experience
Lenalidomide Associated With Transfusion Independence in Low-Risk MDS
F Le Bras, M Sebert, C Kelaidi, T Lamy, F Dreyfus, J Delaunay, A Banos, M Blanc, N Vey, A Schmidt, S Visanica, V Eclache, P Turlure, O Beyne-Rauzy, A Guerci, A Delmer, S de Botton, D Rea, P Fenaux, L Ades
20111001
2011 Nov 1
Leuk Res
Treatment by Lenalidomide in Lower Risk Myelodysplastic Syndrome With 5q Deletion—The GFM Experience
Leuk Res. 2011 Nov 1;35(11):1444-1448, F Le Bras, M Sebert, C Kelaidi, T Lamy, F Dreyfus, J Delaunay, A Banos, M Blanc, N Vey, A Schmidt, S Visanica, V Eclache, P Turlure, O Beyne-Rauzy, A Guerci, A Delmer, S de Botton, D Rea, P Fenaux, L Ades
TAKE-HOME MESSAGE
Abstract
Abstract
We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% of patients. Del 5q was isolated, with 1 additional and >1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count >150 G/L and platelet decrease...
